The US Food and Drug Administration (FDA) has issued a new alert about the potential for increased risk for heart failure in patients taking the type 2 diabetes drugs saxagliptin (Onglyza, AstraZeneca Pharmaceuticals LP) and alogliptin (Nesina, Takeda Pharmaceuticals).
What are the risks and benefits in atrial fibrillation (AF) patients with previous intracranial hemorrhage (ICH) treated with warfarin, compared to antiplatelet or no antithrombotic therapies?
Both rate and rhythm control strategies are safe and effective for patients in atrial fibrillation after cardiac surgery, according to data presented at the American College of Cardiology Scientific Session.
Данный сайт и вся информация на нём предназначена для медицинских работников.
Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.